InterMune Receives Buy Rating from Canaccord Genuity (ITMN)
InterMune (NASDAQ:ITMN)‘s stock had its “buy” rating reaffirmed by equities researchers at Canaccord Genuity in a research report issued on Wednesday, Stock Ratings Network.com reports. They currently have a $17.00 target price on the stock. Canaccord Genuity’s price objective suggests a potential upside of 12.51% from the company’s current price.
A number of other analysts have also recently weighed in on ITMN. Analysts at Goldman Sachs Group Inc. raised their price target on shares of InterMune (NASDAQ:ITMN) from $11.00 to $12.00 in a research note to investors on Wednesday. Separately, analysts at JMP Securities raised their price target on shares of InterMune (NASDAQ:ITMN) from $15.00 to $18.00 in a research note to investors on Thursday, July 25th. They now have a “market outperform” rating on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of InterMune (NASDAQ:ITMN) in a research note to investors on Thursday, July 25th. They now have a $18.00 price target on the stock, up previously from $17.00.
Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. InterMune presently has an average rating of “Buy” and a consensus price target of $16.75.
InterMune (NASDAQ:ITMN) traded up 0.07% during mid-day trading on Wednesday, hitting $15.11. 826,905 shares of the company’s stock traded hands. InterMune has a one year low of $7.80 and a one year high of $16.00. The stock has a 50-day moving average of $14.8 and a 200-day moving average of $11.25. The company’s market cap is $1.238 billion.
InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, July 24th. The company reported ($0.77) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.70) by $0.07. The company had revenue of $14.40 million for the quarter, compared to the consensus estimate of $12.95 million. During the same quarter last year, the company posted $0.01 earnings per share. InterMune’s revenue was up 160.0% compared to the same quarter last year. Analysts expect that InterMune will post $-2.85 EPS for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.